The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Long-term Renal Outcomes in Patients With Primary Aldosteronism
Open accessAbstract
CONTEXT: Experimental animal studies indicate that exposure to increased aldosterone levels might result in renal damage, but the clinical evidence supporting this role of aldosterone is preliminary. OBJECTIVE: To determine the long-term outcome of renal function in patients with primary aldosteronism after surgical or medical treatment. DESIGN, SETTING, AND PARTICIPANTS: Prospective study conducted at an Italian university medical center among a consecutive sample of 50 patients who were diagnosed as having primary aldosteronism between January 1994 and December 2001 and who were followed up for a mean of 6.4 years after treatment with adrenalectomy or spironolactone. Patients with primary aldosteronism were compared with 100 patients with essential hypertension, matched for severity and duration of hypertension. All patients were treated with antihypertensive drugs to reach a target blood pressure of less than 140/90 mm Hg. MAIN OUTCOME MEASURES: Primary outcome measures were rates of change of glomerular filtration rate and albuminuria during follow-up. Detection of new-onset microalbuminuria and restoration of normal albumin excretion during follow-up were considered as secondary outcomes. RESULTS: At baseline, glomerular filtration rate and albuminuria were higher in patients with primary aldosteronism than those with essential hypertension. The mean blood pressure during the study was 136/81 mm Hg in the primary aldosteronism group and 137/81 mm Hg in the essential hypertension group. Glomerular filtration rate and albuminuria declined during the initial 6-month period in both groups, with a change that was significantly greater (P<.001 for both variables) in patients with primary aldosteronism. Subsequent rate of decline of glomerular filtration was comparable in the 2 groups, whereas albuminuria did not progress in the remainder of the follow-up. Restoration of normal albumin excretion from microalbuminuria was significantly more frequent in primary aldosteronism than in essential hypertension (P = .02). CONCLUSION: In the majority of patients in this study, primary aldosteronism was characterized by partially reversible renal dysfunction in which elevated albuminuria is a marker of a dynamic rather than structural renal defect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Random-Effects Models for Longitudinal Data
Laird, N. M., & Ware, J. H. (1982) · Biometrics · doi:10.2307/2529876 · Cited by 8,923
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes].
Parving, H., Lehnert, H., Brøchner‐Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · PubMed · Cited by 2,535
The Effect of Age on Creatinine Clearance in Men: A Cross-sectional and Longitudinal Study
Rowe, J. W., Andres, R., Tobin, J. D., Norris, A. H., & Shock, N. W. (1976) · Journal of Gerontology · doi:10.1093/geronj/31.2.155 · Cited by 1,104
Mulatero (2004) · doi:10.1210/jc.2003-031337 · Cited by 961
Laragh, J. H. (1973) · The American Journal of Medicine · doi:10.1016/0002-9343(73)90128-9 · Cited by 483
Role of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466 · cited 1×
“003) and in patients with adrenal adenoma (from a mean [SD] of 103 [15] to 90 [18] mL/min per 1.”
BackgroundClinical characteristics of primary aldosteronism from an analysis of 145 cases
Conn, J. W., Knopf, R. F., & Nesbit, R. M. (1964) · The American Journal of Surgery · doi:10.1016/0002-9610(64)90252-1 · Cited by 429
Primary Aldosteronism: Factors Associated with Normalization of Blood Pressure after Surgery
Sawka, A. M., Young, W. F., Thompson, G. B., Grant, C. S., Farley, D. R., Leibson, C., & van Heerden, J. A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-4-200108210-00010 · Cited by 347
Chaturvedi, N. (2001) · UCL Discovery (University College London) · Cited by 299
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
The Pathophysiology of Aldosterone in the Cardiovascular System
ROCHA, R., & FUNDER, J. W. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04415.x · Cited by 261
Beneficial impact of spironolactone in diabetic nephropathy
Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L., & Parving, H.-H. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.00756.x · Cited by 239
Relative Glomerular Hyperfiltration in Primary Aldosteronism
Ribstein, J., Du Cailar, G., Fesler, P., & Mimran, A. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004100878 · Cited by 201
Pitt, B., Remme, W., & Zannad, F. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00290-3 · Cited by 187
Plasma aldosterone concentrations in chronic renal disease
Hené, R. J., Boer, P., Koomans, H. A., & Dorhout Mees, E. J. (1982) · Kidney International · doi:10.1038/ki.1982.14 · Cited by 185
Cardiovascular complications in patients with primary aldosteronism
Nishimura, M., Uzu, T., Fujii, T., Kuroda, S., Nakamura, S., Inenaga, T., & Kimura, G. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70298-2 · Cited by 160
Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
Epstein, M. (2001) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(01)80115-3 · Cited by 158
Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
Bianchi, S., Bigazzi, R., & Campese, V. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2005.03.007 · Cited by 140
Plouin, P., Amar, L., & Châtellier, G. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh112 · Cited by 124
Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function
Epstein, M., & Campese, V. M. (2005) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2004.08.040 · Cited by 122
Rapid Inhibition of Vasoconstriction in Renal Afferent Arterioles by Aldosterone
Uhrenholt, T. R., Schjerning, J., Hansen, P., Nørregaard, R., Jensen, B. L., Sørensen, G. L., & Skøtt, O. (2003) · Circulation Research · doi:10.1161/01.res.0000106135.02935.e1 · Cited by 120
Aldosterone as a Cardiovascular Risk Factor
Yoo, S. J. (2007) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2007.22.1.8 · Cited by 112
Ferrari, P., Shaw, S., Nicod, J., Saner, E., & Nussberger, J. (2004) · Journal of Hypertension · doi:10.1097/00004872-200402000-00023 · Cited by 105
Endothelium-Derived Nitric Oxide Modulates Vascular Action of Aldosterone in Renal Arteriole
Arima, S., Kohagura, K., Xu, H.-L., Sugawara, A., Uruno, A., Satoh, F., Takeuchi, K., & Ito, S. (2003) · Hypertension · doi:10.1161/01.hyp.0000111138.78714.1a · Cited by 94
Relationship of Fibrinogen Levels and Hemostatic Abnormalities With Organ Damage in Hypertension
Sechi, L. A., Zingaro, L., Catena, C., Casaccio, D., & Marchi, S. D. (2000) · Hypertension · doi:10.1161/01.hyp.36.6.978 · Cited by 90
Self-citationRenal function curve in patients with secondary forms of hypertension.
Kimura, G., Saito, F., Kojima, S., Yoshimi, H., Abe, H., Kawano, Y., Yoshida, K., Ashida, T., Kawamura, M., & Kuramochi, M. (1987) · Hypertension · doi:10.1161/01.hyp.10.1.11 · Cited by 79
Sechi, L. A., Kronenberg, F., Carli, S. D., Falleti, E., Zingaro, L., Catena, C., Utermann, G., & Bartoli, E. (1997) · JAMA · doi:10.1001/jama.1997.03540450045033 · Cited by 77
Self-citationBeevers, D. G., Brown, J. J., Ferriss, J. B., Fräser, R., Lever, A. F., Robertson, J. I. S., & Tree, M. (1976) · QJM · doi:10.1093/oxfordjournals.qjmed.a067470 · Cited by 71
The challenge of more robust and reproducible methodology in screening for primary aldosteronism
Gordon, R. D. (2004) · Journal of Hypertension · doi:10.1097/00004872-200402000-00006 · Cited by 69
Aldosterone receptor blockade and the role of eplerenone: evolving perspectives
Epstein, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg339 · Cited by 62
Sechi, L. A., Zingaro, L., Catena, C., Perin, A., Marchi, S. D., & Bartoli, E. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00621.x · Cited by 58
Self-citationPrimary Hyperaldosteronism without Suppressed Renin Due to Secondary Hypertensive Kidney Damage
Oelkers, W., Diederich, S., & Bähr, V. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6819 · Cited by 46
Aldosterone in progressive renal disease
Hostetter, T. H., Rosenberg, M. E., Ibrahim, H. N., & Juknevicius, I. (2001) · Seminars in Nephrology · doi:10.1053/snep.2001.26797 · Cited by 39
Epstein, M., Buckalew, V. M., Altamirano, J. H., Roniker, B., Krause, S. L., & Kleiman, J. H. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)81115-9 · Cited by 36
Die Jaffé-Reaktion mit Kreatinin Reaktionsprodukt und allgemeine Reaktionsbedingungen
Seelig, H. P. (1969) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1969.7.6.581 · Cited by 36
The Shocking Tooth about Trigeminal Neuralgia
Cheshire, W. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422619 · Cited by 15
Influence of galvanic phenomena on the occurrence of algic symptoms in the mouth.
Kucerová, H., Dostálová, T., Procházková, J., Bártová, J., & Himmlová, L. (2002) · PubMed · Cited by 14
Cited by
Williams, T. A., Lenders, J. W. M., Mulatero, P., Burrello, J., Rottenkolber, M., Adolf, C., Satoh, F., Amar, L., Quinkler, M., Deinum, J., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30135-3 · Cited by 969
Self-citationPrimary aldosteronism: renaissance of a syndrome
Young, W. F. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.02775.x · Cited by 680
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment
Catena, C. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.33 · Cited by 565
Self-citationDouma, S., Petidis, K., Doumas, M., Papaefthimiou, P., Triantafyllou, A., Kartali, N., Papadopoulos, N., Vogiatzis, K., & Zamboulis, C. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60834-x · Cited by 560
Metadata
- Authors
- Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G. L., & Catena, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2006-06-14
- Volume
- 295
- Issue
- 22
- Pages
- 2638-45
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2061764902
- Cited by
- 388
- References
- 41
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.